Management and board changes at Oxford BioMedica
This article was originally published in Scrip
Oxford BioMedica, a gene therapy company, has appointed Dr Alex Lewis director of corporate activities and strategy. He will step down from Oxford BioMedica's board to be replaced by Dr Paul Blake, who will become chairman of the company's remuneration committee, and Dr Andrew Heath who will also join the committee. Dr Lewis was appointed to Oxford BioMedica's board in April 2008 and was also director of transactions and due diligence at The Datamonitor Group until June 2009.